Carfilzomib: Phase Ib data

Preliminary data from 14 patients in the Phase Ib portion of an open-label, dose-escalation, U.S. Phase Ib/II trial showed that IV carfilzomib was well-tolerated at doses up to 36 mg/m 2 with a low in...